LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

Search

Cassava Sciences Inc

Closed

SectorHealthcare

1.83 -1.61

Overview

Share price change

24h

Current

Min

1.82

Max

1.86

Key metrics

By Trading Economics

Income

4.2M

-23M

EPS

-0.485

Employees

30

EBITDA

5.7M

-24M

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

19M

96M

Previous open

3.44

Previous close

1.83

News Sentiment

By Acuity

47%

53%

163 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Cassava Sciences Inc Chart

Past performance is not a reliable indicator of future results.

Related News

27 Sept 2024, 10:48 UTC

Major Market Movers

Cassava Sciences Shares Lower Premarket on $40 Million Penalty to Settle Doctored Data Claims

28 Jun 2024, 20:15 UTC

Major Market Movers

Cassava Sciences' Shares Down 46% After Adviser Is Indicted

27 Sept 2024, 18:36 UTC

Earnings

These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More -- Barrons.com

27 Sept 2024, 09:15 UTC

Hot Stocks

Stocks to Watch Friday: Bristol Myers Squibb, EchoStar, Costco -- WSJ

Peer Comparison

Price change

Cassava Sciences Inc Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

1.56 / 1.7Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

163 / 380 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.